Vivos Therapeutics Stock Jumps 36% on Debt-to-Equity Swap to Meet Nasdaq Rule
Vivos Therapeutics shares surged 36% after a $4.5 million debt-to-equity swap with Streeterville Capital to address Nasdaq compliance, though the deal depends on new equity financing.
Markets
